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Abstract
 
The signal transducer and activator of transcription (STAT) family proteins are transcription
factors critical in mediating cytokine signaling. Among them, STAT3 is often constitutively
phosphorylated and activated in human cancers and in transformed cell lines and is implicated
in tumorigenesis. However, cause of the persistent activation of STAT3 in human tumor cells
is largely unknown. The hepatitis C virus (HCV) is a major etiological agent of non-A and
non-B hepatitis, and chronic infection by HCV is associated with development of liver cirrho-
sis and hepatocellular carcinoma. HCV core protein is proposed to be responsible for the virus-
induced transformation. We now report that HCV core protein directly interacts with and ac-
tivates STAT3 through phosphorylation of the critical tyrosine residue. Activation of STAT3
by the HCV core in NIH-3T3 cells resulted in rapid proliferation and up-regulation of Bcl-XL
and cyclin-D1. Additional expression of STAT3 in HCV core-expressing cells resulted in
anchorage-independent growth and tumorigenesis. We propose that the HCV core protein
cooperates with STAT3, which leads to cellular transformation.
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Introduction
 
The signal transducer and activator of transcription
(STAT)
 
*
 
 family proteins were identified in the last decade
as transcription factors essential for mediating virtually all
cytokine signaling (1, 2). These proteins become activated
through tyrosine phosphorylation, which typically occurs
through cytokine receptor–associated kinases, the Janus ki-
nase (JAK) family proteins (3). In addition to their central
roles in normal cell signaling, recent studies have demon-
strated that constitutively activated STAT signaling, espe-
cially STAT3, directly contributes to oncogenesis (4). For
example, all 
 
src
 
 transformed cell lines exhibit constitutively
activated Stat3 (5), and dominant-negative Stat3 suppresses
 
src
 
 transformation without having any effect on 
 
ras
 
 transfor-
mation (6, 7). More directly, Bromberg et al. (8) demon-
strated that a constitutively activated form of STAT3,
STAT3-C, which has two substituted cysteine residues
within the COOH-terminal loop of the SH2 domain, re-
sulting in a spontaneous transcriptionally active dimer,
causes cellular transformation scored by colony formation
in soft agar and tumor formation in nude mice. Thus, the
activated Stat3 molecule by itself can mediate cellular trans-
formation. Extensive surveys of primary tumors and cell
lines derived from tumors have indicated that an inappro-
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priate activation of STAT3 occurs at a surprisingly high fre-
quency in a wide variety of human cancers (9). However,
mutations in the STAT3 gene have not been identified in
these cancers, hence it remained to be determined how en-
dogenous STAT3 is constitutively activated.
The hepatitis C virus (HCV), a major etiological agent of
non-A and non-B hepatitis, leads to chronic infection and
ultimately to liver cirrhosis and hepatocellular carcinoma
(HCC; references 10 and 11). Globally, there are 0.25–1.2
million new cases of HCC annually, hence HCV is one of
the major infectious causes of morbidity and mortality
worldwide (12). HCV is a positive-strand RNA virus that
consists of an 
 
 
 
9,600 base, and the open reading frame ge-
nome encodes a polyprotein of 3,010 amino acids, processed
by cellular and viral proteases into three to four putative
structural (core, E1, E2/p7) and at least six nonstructural
(NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins. Among
these, the HCV core protein derived from the NH
 
2
 
-termi-
nal 191 amino acids of the precursor polyprotein has been
implicated in cellular transformation. This was demonstrated
in one transgenic (Tg) mouse line expressing the core pro-
tein in liver, which induce HCC (13), although this has
been highly debated and there are several HCV core-Tg
mouse lines that do not develop HCC. The transforming
potential of the core itself has been shown to be weak; the
core protein can transform fibroblastic cells in collaboration
with other oncogenes, such as Ras. Therefore, it has been
suggested that additional factors may be necessary for induc-
tion of cellular transformation by the HCV core. Kato and
coworkers demonstrated that among HCV and hepatitis B
virus (HBV) structural and nonstructural proteins, HCV
core protein is the most potent signal inducer determined by
using various reporter assays with the cAMP response ele-
ment, the serum response element (SRE), and elements
containing binding sites for nuclear factor (NF)-
 
 
 
B, activa-
tor protein 1 (AP-1), and serum response factor (SRF; refer-
ence 14). The HCV core protein also affects several tran-
scription factor activities including LZIP and Elk-1;
however, the role of these transcription regulators in core-
mediated transformation is unclear (15, 16).
We now report that the HCV core protein interacts di-
rectly with STAT3 and selectively activates it. Activation
of STAT3 by the HCV core in NIH-3T3 cells resulted in
STAT3-dependent rapid proliferation and up-regulation of
Bcl-XL and cyclin-D1. The core protein can also transform
NIH-3T3 cells in collaboration with additional expression
of wild-type STAT3. These data suggest that the constitu-
tive activation of STAT3 plays an important role in trans-
formation by the HCV core protein.
 
Materials and Methods
 
Core-Tg Mice and Carcinogen Treatment.
 
The Tg mouse was
generated using a construct carrying HCV-core cDNA (HCV-1b
strain) fused to the promoter of the HBV X gene (Px) (pPx-core;
reference 17). Tg mice were developed using the conventional
methods. (C57BL/6 
 
 
 
 DBA/2) F1 mice were used to obtain fer-
tilized eggs, and those founder mice were mated with C57BL/6
 
mice for over five generations. Expression of HCV core protein
has been published (17). The core protein was expressed in vari-
ous tissues including brain, heart, lung, kidney, thymus, and liver.
However, protein levels in the liver were about one third of
those in the spleen and other tissues.
4-wk-old male mice were given a single injection (intraperito-
neal) of diethylnitrosamine (DEN; Sigma-Aldrich) at 10 
 
 
 
g/g of
body weight as described (18). 2 d later, these mice were killed,
and portions of three liver lobes were used for immunoblotting
and immunohistochemical studies. For immunoblotting, liver ex-
tracts were prepared by homogenizing tissue in extraction buffer
(50 mM HEPES, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM
EDTA, 1 mM vanadate). The protein concentration of each liver
extract was determined using the DC Protein assay system (Bio-
Rad Laboratories) according to manufacturer’s directions. Subse-
quent immunoblot analysis was done using 20 
 
 
 
g of total liver
protein as described below.
Immunohistochemical detection of cyclin D1 and proliferating
cell nuclear antigen (PCNA) was performed using formalin-fixed,
deparaffinized mouse liver tissue sections and anti-PCNA and
anti-cyclin D1 antibodies (Santa Cruz Biotechnology, Inc.), as
described (18). Antibody-protein complexes were visualized us-
ing SAB kit (Dako) and 3,3
 
 
 
-diaminobenzidine according to the
manufacturer’s directions.
 
Core and HCV cDNA.
 
The HCV core region (573 nucle-
otides) was also amplified by RT-PCR, using HCV RNA as a
template extracted from the serum of a patient with chronic hep-
atitis C, genotype 1b. The nucleotide sequence is 98% and amino
acid sequence is 100% identical to those of HCV strain MD7–1
(19). The cDNA was subcloned into expression vector pcDNA3
with the NH
 
2
 
-terminal Myc tag (six repeats; reference 20)
(pcDNA3-Myc-core) or Flag-tagged vector (pCMV2-flag; Ko-
dak; pFlag-core). This clone was used for most of the experi-
ments in this study. Another core cDNA genotype 1b (21) was
subcloned into the pEF1 vector (pEF-core; Invitrogen). Full-
genome HCV cDNA was also cloned from the serum of a
chronic hepatitis patient and subcloned into the Cre/loxP condi-
tional expression cassette (pCALN) using a neo-resistant gene
with poly A signal as a stuffer (21). For this study, the Cre/loxP
cassette was removed by digestion with XhoI. Expression of all
HCV proteins, including the core, E1, E2, NS1, NS2, NS3,
NS4A, NS4B, NS5A, and NS5B were confirmed by Western
blotting (unpublished data). Details on the construction of this
plasmid will be published elsewhere.
 
Cells and Transfection.
 
HepG2 cells and NIH 3T3 cells were
cultured in DMEM containing 10% FCS and 10% calf serum
(CS), respectively. Transient transfections of expression into
HepG2 cells and NIH 3T3 were done using TransFast (Promega)
or Fugene 6 transfection reagents (Roche). The transfection effi-
ciency for HepG2 cells was 50–70%. An APRE-luciferase re-
porter gene for STAT3 activity (20) and a reporter gene construct
containing IFN
 
 
 
-responsive ISRE (IFN-stimulating factor re-
sponsive element)-luciferase for IFN-stimulated gene factor 3
were as described previously (22). Luciferase assays were done us-
ing the dual-luciferase reporter system (Promega). cDNA for v-
 
src
 
in pcDNA3 was provided by Dr. Hamanaka (Nagoya University,
Japan). The expression plasmid of Flag-tagged STAT3-C in pRc-
CMV was provided by Dr. Darnell, Jr., The Rockefeller Univer-
sity, New York, NY (8). To create Flag-tagged wild-type
STAT3, STAT3-C was replaced with WT-STAT3 cDNA.
 
Retrovirus Construction and Infection.
 
The myc-tagged core
cDNA was subcloned into a bicistronic retrovirus vector, pMX-
IRES-EGFP (enhanced green fluorescent protein; reference 23). 
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A retrovirus was produced by transient transfection of a PLAT-E
packaging cell line (24). 48 h after transfection, the culture super-
natant was harvested, and NIH-3T3 cells (2 
 
 
 
 10
 
5
 
 cells) were in-
fected with appropriately diluted PLAT-E supernatant with 10
 
 
 
g/ml polybrene for 24 h. 100% infection was confirmed by
EGFP fluorescence. Infected cells were expanded for 2–5 d, then
immediately used for proliferation and colony-formation assays.
 
Adenovirus.
 
Adenoviral vectors containing the genes for lacZ
(Ad-lacZ), Myc-tagged SOCS3 (Ad-SOCS3), and HA-tagged
Y705F-STAT3 (Ad-dnSTAT3) were prepared via homologous
recombination in 293 cells as described (25). The viral prepara-
tions were titrated with a plaque-forming assay on 293 cells. The
number of virus particles (measured in PFU) per cell was ex-
pressed as multiplicity of infection (MOI). The adenovirus was
inoculated at MOI 
 
 
 
 50, and 100% of the cells were infected, as
assessed by lacZ staining. The cells were used for experiments im-
mediately after infection.
 
Transformation Assay.
 
4–6-wk-old athymic, Balb-c/nu/nu
mice were injected with 10
 
6
 
 cells from various cell lines in 0.2 ml
PBS. After 3 wk, the tumors were measured. Each cell line was
tested in 2–3 different mice.
 
Binding Assay.
 
Full-length core cDNA was ligated into a
pGEX-4T vector to create the GST-fused core protein (GST-
core). HepG2 cell extracts stimulated either with or without leu-
kemia-inhibitory factor (LIF) were incubated with beads contain-
ing the GST or GST-core for 1 h at 4
 
 
 
C. After extensive washing,
proteins bound to the beads were eluted by boiling in an
SDS-sample buffer and immunoblotted with anti-STAT3, anti-
ERK2, anti-NF-
 
 
 
B p65 subunit, or anti-GST antibodies (Santa
Cruz Biotechnology, Inc.). A series of NH
 
2
 
-terminal and
COOH-terminal deletion mutants of STAT3 and the core were
generated by PCR and subcloned into pcDNA3-myc or
pCMV2-flag vectors. These cDNAs were transiently expressed in
293 cells (1 
 
 
 
g plasmid/transfection) and cell extracts were im-
munoprecipitated with either anti-Myc polyclonal antibody
(Santa Cruz Biotechnology, Inc.) or anti-flag (M2; Eastman
Kodak Co.), then analyzed by immunoblotting with anti-Myc
(9E10) or anti-Flag antibodies.
 
Immunoprecipitation and Western Blot Analysis.
 
Cells were
lysed in the lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl,
0.5% NP-40, 1 mM EDTA, 1 mM vanadate, 1 mM DTT, 0.1
mM APMSF) and centrifuged at 12,000 
 
g
 
 for 10 min. Before the
precipitation experiments, BSA were added at final concentra-
tions 1 mg/ml, then, the supernatants were incubated with the
indicated antibodies at 4
 
 
 
C for 1 h. Immune-complexes were
precipitated with protein A-Sepharose (Amersham Biosciences).
After washing three times with lysis buffer, the immunoprecipi-
tates were resolved with SDS-PAGE and immunoblotted with
the indicated antibodies as described (20). Nuclear and cytoplas-
mic extracts were prepared as described (8). Briefly, cells were
scraped off the dish and pelleted; 3
 
 
 
 the pellet volume of cyto-
plasmic buffer was added (20 mM HEPES, pH 7.9, 10 mM KCl,
0.1 mM NaVanadate, 1 mM EDTA, 10% glycerol, 1 mM DTT,
1 mM PMSF), then left on ice for 10 min. The sample was lysed
using a dounce homogenizer (10–20 strokes) and spun in an Ep-
pendorf centrifuge for 5 min. The supernatant is the cytoplasmic
fraction. The pellet was washed once with cytoplasmic buffer,
then resuspended in 2
 
  
 
the pellet volume with nuclear buffer
(420 mM NaCl, 20% glycerol, 20 mM HEPES, pH 7.9, 10 mM
KCl, 1 mM EDTA, 0.1 mM NaVanadate, 1 mM PMSF, 1 mM
DTT). 10 
 
 
 
g of each sample was used for immunoblotting with
anti-STAT3 antibody. Anti-HCV core monoclonal antibody was
purchased from Arista Biological Inc. Anti-JAK2 was purchased
 
from UBI; anti-tyrosine-phosphorylated STAT1, anti-tyrosine-
phosphorylated STAT3, anti–tyrosine-phosphorylated STAT5,
and anti–tyrosine-phosphorylated STAT6 were from Cell Signal-
ing Technology; anti–tyrosine-phosphorylated JAK1 and JAK2
was from Quality Controlled Biochemicals, Inc.; anti-STAT1,
anti-STAT3, anti-STAT5, anti-ERK2, anti-cyclin-D1, anti-
bcl-X, anti-NF-kB p65 subunit, and anti-GST were from Santa
Cruz Biotechnology, Inc.
 
Results
 
The HCV-Core Protein Induces Activation of STAT3.
 
It
has been shown that a Tg expression of the HCV core pro-
tein in mice resulted in HCC in one case (13). We also de-
veloped HCV core Tg mice (Px-core Tg), in which the
core protein is expressed ubiquitously (17). Malignant tu-
mors (6 out of 22) developed in the skin and muscle of Px-
core Tg mice up to 13 mo of age, whereas no tumors
developed in their nontransgenic littermates. No HCC de-
veloped in our Tg mice, maybe because of relatively low
levels of expression of the core protein in the liver. Simi-
larly, it has been shown that Tg mice harboring the HBV X
protein have only minor histopathologic alterations of the
liver. However, injection of DEN resulted in a twofold in-
crease in the incidence of HCC in the Tg mice compared
with wild-type littermates (26). The extent of hepatocellu-
lar proliferation, as measured by the detection of PCNA
and by the incorporation of 5-bromo-2
 
 
 
-deoxyuridine, was
approximately twofold higher in the HBV-X protein Tg
livers than in the wild-type (18). Thus, we asked if HCV
core protein also contributes to induction of a premaligant
stage in the liver after treatment with DEN. As shown in a
new Fig. 1 A, the number of cyclin D1 positive hepato-
cytes were 
 
 
 
1.5 times higher than the wild-type litter-
mates. Similar results were obtained for PCNA staining
(unpublished data). These data strongly suggest that the
HCV core associates with dysregulated proliferation, which
may ultimately lead to cellular transformation.
As constitutive activation of STAT3 often occurs in hu-
man tumors and STAT3 activation correlates with prolif-
eration and antiapoptosis (27), we determined if the HCV
core protein would affect STAT3 activity in the liver of
Px-core Tg mice. Immunoblotting with an anti-phosphor-
ylated STAT3-specific antibody revealed that phosphory-
lation occurred in tyrosine 705 (Y705) of STAT3 in two
independent Tg mice livers, an event critical for dimeriza-
tion and DNA binding, but not so in nontransgenic litter-
mates (Fig. 1 B, lanes 1–4). Next, we examined the effect
of DEN on STAT3 activation in the liver. 2 d after DEN
injection, liver extracts were prepared. Tyrosine phos-
phorylation of STAT3 was much stronger in DEN-treated
livers of Tg mice than in wild-type mice (Fig. 1 B, lanes
5–8). As STAT5 was not phosphorylated in Tg and wild
type mice (Fig. 1 B, lanes 9 and 10), these data suggest
that the core protein specifically induces and enhances
STAT3 activation.
As illustrated in Fig. 2, A and B, STAT3 transcription
activity was significantly increased by transient expression 
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of the core protein in both HepG2 cells and NIH 3T3
cells, and STAT3 transcription activity by the core protein
was further enhanced by LIF stimulation. In contrast, the
HCV core protein did not affect interferon (IFN)
 
 
 
-
induced reporter (ISRE-reporter) activity which reflects
STAT1 and STAT2 activation (Fig. 2 C). Similar STAT3
activation by the core was observed in different cell types,
including 293 cells and Hela cells (unpublished data). The
core protein did not affect IFN
 
 
 
-induced STAT1 or EPO-
induced STAT5 activation (unpublished data). Consistent
with these findings, STAT3, but not STAT1 or STAT5,
was significantly tyrosine-phosphorylated when the HCV
core protein was expressed in HepG2 cells (Fig. 2 D, a, b,
and c). STAT3 activation was observed by different core
protein constructs derived from three independent HCV
(genotype 1b) from different patients (Fig. 2 E, lanes 1–3).
Expression of the full length HCV genome resulted in
stronger STAT3 activation than did the core protein alone
(Fig. 2 E, lane 4).
Interestingly, JAK1 as well as JAK2 was not activated by
core-protein expression (Fig. 2 D, d and e). Furthermore,
core-induced STAT3 phosphorylation was not blocked by
AG490, a JAK inhibitor (Fig. 2 F, lanes 2 and 3), whereas
AG490 efficiently blocked LIF-induced STAT3 activation
(lanes 4 and 5). We have not examined Tyk2. However, it
 
is very unlikely that this kinase is involved, as SOCS3 ade-
novirus did not inhibit STAT3 activation by the core (see
Fig. 5 D). These data indicate that the core protein acti-
vates STAT3 through cytokine receptor and JAK indepen-
dent mechanisms.
 
Direct Interaction between the Core and STAT3.
 
Activa-
tion of STAT3 by the core protein suggests a direct inter-
action between these two proteins. As shown in Fig. 3,
STAT3 bound to the core both in vitro and in vivo. Both
phosphorylated and nonphosphorylated forms of STAT3
bound to the GST-fused core protein in vitro (Fig. 3 A).
We examined whether the core protein directly interacts
with ERK2 (MAP kinase) or the NF-
 
 
 
B p65 subunit, as
the core has been shown to activate MAP kinase and NF-
 
 
 
B under certain circumstances (14, 16). We observed no
direct interaction of the core with these proteins in vitro
(Fig. 3 A).
Next, we determined the region of STAT3 responsible
for binding to the core. As shown in Fig. 3, B and C,
binding experiments using truncated forms of STAT3 re-
vealed the linker region of STAT3 to be essential for in-
teraction with the core protein. For the core protein, 
 
 
 
C2
(1–113) bound and transactivated STAT3, whereas 
 
 
 
C3
(1–75) did not do so; thus residues 75–113 were impor-
tant. Similarly, 
 
 
 
N2 (91–191) but not 
 
 
 
N3 (120–191)
Figure 1. Proliferation and STAT3 acti-
vation of liver cells in HCV core protein Tg
mice. (A) Representative immunohis-
tochemical staining of Cyclin D1 in DEN-
treated Px core Tg mouse and wild-type
mouse liver tissue sections (original magnifi-
cation,   200). Cyclin D1–positive nuclei
are in brown, and nonlabeled nuclei were
counterstained with hematoxylin. In the
right panel, the percentage of Cyclin D1–
positive hepatocytes in DEN-treated mouse
liver (n   4). Mean values were determined
by counting Cyclin D1–positive hepato-
cytes in five random fields of  250 cells per
field. Error bars represent standard devia-
tions. (B) Phosphorylation of STAT3. Two
Tg mouse lines (core-Tg1 and core-Tg2;
lanes 3, 4, 7, 8, and 10) and their littermates
(non-Tg1 and non-Tg2; lanes 1, 2, 5, 6, and 9) were treated without (lanes 1–4, 9, 10) or with (lanes 5–8) DEN. 2 d later, liver cell extracts (20  g pro-
tein/lane) were prepared and immunoblotted with anti-phospho-STAT3 (PY-STAT3), STAT3, phospho-STAT5 (PY-STAT5), STAT5, and HCV
core antibodies. 
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bound and activated STAT3; thus resides 91–120 were
important. Based on these findings, amino acids 91–113
are essential not only for STAT3 binding but also for
STAT3 transcriptional activation (Fig. 3, D–F). These data
indicate that the core protein directly interacts with
STAT3, which leads to tyrosine phosphorylation and the
activation of STAT3.
The core protein locates mostly in the cytoplasm, but a
significant fraction was also seen in the nucleus (28). A
subcellular fractionation study indicates that small fraction
of STAT3 was translocated to the nucleus in the presence
of core protein (Fig. 4 A, lane 4). LIF induced transloca-
tion of STAT3 in the nucleus (lane 6), and nuclear local-
ization of STAT3 was further enhanced in the presence of
Figure 2. Activation of
STAT3 by HCV core protein.
(A–C) Reporter gene assay.
HepG2 (A and C) or NIH-3T3
(B) cells were transfected with
0.5, 1, or 2  g plasmid of the
pcDNA3-Myc-core and then
stimulated by either 10 ng/ml
LIF (A and B) or 100 ng/ml
IFN  (C) for 6 h. STAT3- (A
and B) or ISRE- (C) dependent
luciferase activity was measured.
(D) Phosphorylation of STAT3
by the core protein. HepG2 cells
were transfected with 0 (lanes 1
and 5), 0.5 (lane 2), 1 (lane 3), 2
(lane 4)  g of the core plasmid,
and STAT3 (a), STAT1 (b),
STAT5 (c), JAK1 (d), and JAK2
(e) were then immunoprecipi-
tated. The immunoprecipitates
were blotted with anti-phosphor-
ylated forms-specific antibod-
ies. As a positive control (lanes
5), cells were stimulated with
LIF or IFN  for STAT3,
STAT1, and JAK1 phosphoryla-
tion. For STAT5, 293 cells
transfected with the Erythropoi-
etin (Epo) receptor (Epo-R)
were stimulated with Epo. (E)
Activation of STAT3 by three
independent HCV core cDNAs
and full-length HCV genomic
DNA. pcDNA3-Myc-core
(core-1, lane 1), pPx-core (core-2,
lane 2), pEF-core (core-3,
lane 3), and pCALN-HCV
(HCV-full, lane 4) were tran-
siently expressed in HepG2 cells
then, total cell extracts were
immunoblotted with indicated
antibodies. (F) HepG2 cells
transfected with empty vector
pcDNA3-Myc (lane 1) or with
pcDNA3-Myc-core (lanes 2 and
3) or untransfected cells (lanes 4
and 5) were treated without
(lanes 1–3) or with (lanes 5 and
6) 10 ng/ml LIF for 3 h, then
further incubated with (lanes 3
and 5) or without (lanes 1, 2, and
4) AG490 (50  M) for 6 h. To-
tal cell extracts were immuno-
blotted with anti-PY-STAT3 or
anti-STAT3 antibodies. 
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the core protein (lane 8). We then examined the subcellu-
lar localization of the core and phosphorylated STAT3,
using immunofluorescence microscopy. As expected,
phosphorylated STAT3 colocalized with the core protein
in HepG2 and NIH-3T3 cells (Fig. 4 B); mostly in the cy-
toplasm, but there was a small fraction in the nucleus.
Treatment of cells with LIF accelerated translocation of
STAT3 in the nucleus. However, a significant fraction of
the phosphorylated STAT3 was still present in the cyto-
plasm in the core-transfected cells, while phosphorylated
STAT3 was mostly present in the nucleus in nontrans-
fected cells. Such cytoplasmic retention of phosphorylated
STAT3 in the presence of the core protein also supports
the notion of a strong interaction between STAT3 and the
core protein.
Although the molecular mechanism of selective STAT3
phosphorylation by the core is not clear, we suspect that
STAT3-core interaction may prevent dephosphorylation.
Figure 3. Interaction between the core protein and STAT3. (A) In vitro binding experiment. HepG2 cell extracts stimulated with ( ) or without ( )
LIF were incubated with either GST or GST-core bound to glutathione-Sepharose. Aliquots of total cell extracts (TCL) and proteins bound to the beads
were immunoblotted with anti-STAT3, anti-NF- B p65, and anti-ERK2 antibodies. Purified GST and GST-core fusion protein (0.1  g protein) was
also blotted with anti-GST. (B) Schematic diagrams of structural domains and deletion mutants of STAT3. (C) Flag-tagged STAT3 deletion mutants and
the myc-tagged core were coexpressed in 293 cells and then immunoprecipitated with either anti-Myc or anti-Flag antibodies. The total cell extracts
(TCL) or immunoprecipitates (IP) were blotted with anti-Myc or anti-Flag antibodies. To confirm the lack of binding between the core protein and
 L-TA construct, data of a separate experiment are shown in the right (exp. 2). (D) Schematic diagrams of the deletion construct of the core protein. (E)
HepG2 cells were transfected with an APRE-luciferase reporter gene and an increased amount of indicated core deletion mutants. After 24 h transfec-
tion, luciferase activity was measured. (F) The 293 cells were transfected with flag-tagged STAT3 and myc-tagged core deletion mutants. Immunopre-
cipitates with anti-Myc antibody or TCL were blotted with anti-Flag and anti-Myc antibodies. 
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Thus, dephosphorylation of phosphorylated STAT3 was
compared by incubating cells with a protein synthesis in-
hibitor cycloheximide. As shown in Fig. 4 C, phosphoryla-
tion of STAT3 was sustained by the core protein expres-
sion. This suggests that the HCV core protein either
protects STAT3 from phosphatases or recruits unknown
tyrosine kinase(s) to STAT3, thereby inducing the consti-
tutive phosphorylation of STAT3.
 
Core-induced Promotion of Proliferation Is Dependent on
STAT3.
 
Next, we directed attention to the effect of
HCV core protein on biological functions of STAT3.
NIH-3T3 cells were infected with a retrovirus (pMX) car-
rying the core cDNA. As shown in Fig. 5 A, overexpres-
sion of the core resulted in an increased proliferation rate in
NIH-3T3 cells, yet the core protein expression alone did
not induce cellular transformation (see Fig. 6). Potent
STAT3 phosphorylation was observed in NIH-3T3 trans-
formants (NIH-3T3/core) expressing the core protein (Fig.
5 B). To examine the role of STAT3 on core-dependent
hyperproliferation, NIH-3T3/core cells were further in-
fected with adenovirus carrying lacZ (control), SOCS3, or
Y705F-STAT3 (25; Fig. 3 C). Y705F-STAT3 has been
shown to function as a dominant negative form of STAT3
(dnSTAT3; reference 29). As dnSTAT3 can bind to the
core (unpublished data), overexpression of dnSTAT3 se-
questers the core protein form endogenous STAT3. On
the other hand, SOCS3 binds to gp130 as well as to JAKs
and inhibits JAK tyrosine kinase activity (30, 31). We con-
firmed that both SOCS3- and dnSTAT3-adenovirus infec-
tion completely inhibited LIF-induced STAT3 activation
and IL-6–dependent proliferation of synovial cells from pa-
tients with rheumatoid arthritis, but did not affect prolifer-
ation of parental NIH-3T3 cells (25). As shown in Fig. 5,
C and D, overexpression of dominant negative STAT3 re-
duced the growth rate of NIH-3T3/core cells to levels
seen in parental NIH-3T3 cells, and diminished the phos-
phorylation of STAT3, whereas SOCS3 did not strongly
affect growth rate or phosphorylation status. Similar
growth suppression by dnSTAT3 was observed using
HepG2 stable transformants expressing the core protein
(unpublished data). These data confirmed that the growth-
promoting activity of the core protein depends on STAT3
but core-mediated STAT3 activation is independent of the
cytokine/JAK pathway.
Figure 4. Nuclear localization of STAT3 (A and B)
and time course of dephosphorylation of STAT3 (C).
HepG2 cells transfected with empty vector (lanes 1, 2, 5,
and 6) or pcDNA3-Myc-core (lanes 3, 4, 7, and 8) were
stimulated without (lanes 1–4) or with (lanes 5–8) 10 ng/
ml LIF for 30 min. Nuclear (N) and cytoplasmic (C) ex-
tracts (20  g each) were analyzed by immunoblotting
with anti-STAT3 antibody. (B) HepG2 cells were trans-
fected with Myc-tagged core cDNA and then immuno-
stained with anti-myc (monoclonal; red) or anti-phos-
phorylated STAT3 (polyclonal; green) antibodies followed by incubation with FITC-and Cy3-conjugated secondary antibodies. White arrowheads
indicate the position of core-transfected cells, and yellow arrowheads indicate nontransfected cells. Similar results were obtained by at least three indepen-
dent experiments. (C) Time course of dephosphorylation. HepG2 cells transfected with or without the core cDNA (transfection efficiency was  60%)
were stimulated with 10 ng/ml LIF for 30 min before cycloheximide (CHX) treatment. The cells were washed and incubated without LIF in the pres-
ence of 100  g/ml CHX for the indicated periods. The immunoprecipitates with anti-STAT3 antibody were analyzed by immunoblotting with the in-
dicated antibodies. The levels of phosphorylated STAT3 in nontransfected (open circle) and transfected (closed circle) cells were quantitated by densi-
tometry of the immunoblots using NIH Image software. 
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Transformation by the Core Requires STAT3 Activation.
 
Next, we examined effects of core protein on cellular
transformation. Recent studies suggested that STAT3 is
necessary for the full transforming activity of 
 
v-src
 
 and that
a constitutively activated form of STAT3 (STAT3-C)
transformed normal fibroblasts (5–7). Thus, we examined
the transforming potential of the core protein in combi-
nation with wild-type (WT)-STAT3 or STAT3-C. As
shown in Table I and Fig. 6 A, expression of only the
core (pMX-core) or transfection of the WT-STAT3 did
not produce colonies in soft agar. However, transfection
of WT-STAT3 into NIH-3T3 cells infected with the
pMX-core did result in colony formation. The efficiency
of colony formation and colony size by WT-STAT3 and
the core (WT-STAT3/core) were comparable to those
seen with STAT3-C (Fig. 6 A and Table I). The combi-
nation of the core and STAT3-C further increased col-
ony formation efficiency (Table I). Cells were recovered
from these transformed colonies and cultured. The levels
of exogenous WT-STAT3 in these cells formed in soft
agar were 1.5–2 times higher than endogenous STAT3
(Fig. 6 B), and both exogenous and endogenous STAT3
were tyrosine phosphorylated by the core (see Fig. 8).
Therefore, the level of STAT3 is critical for transforma-
tion by the core protein. Requirement of further STAT3
expression for transformation in NIH-3T3 cells may be
due to relatively low contents of STAT3 in this fibroblas-
tic cell line compared with contents in the hepatocarci-
noma cell line HepG2 and mouse liver tissues (Fig. 6 B,
and unpublished data).
We then directly compared the plating efficiency in soft
agar of newly established WT-STAT3/core transformed
cell lines to that of STAT3-C transformed cells. The num-
ber of colonies formed per cell plated (plating efficiency) in
WT-STAT3/core cells was comparable to that seen in
STAT3-C (Table I). The colony-forming ability by WT-
STAT3 and the core was significantly reduced by the dom-
inant-negative STAT3 adenovirus but not by the SOCS3
virus (Fig. 6, A and B), thereby indicating that constitutive
STAT3 activation plays an important role in colony-form-
ing potential in soft agar.
Next, the tumorigenicity of cells transformed with wild-
type STAT3 and the core was determined. When 10
 
6
 
 cells
from either of two WT-STAT3/core clones were injected
subcutaneously into nude mice, tumors became apparent at
the injection site within 2 to 4 wk. These tumors were as
large as those of cells transformed with STAT3-C (Table II
and Fig. 7 A). Hematoxylin and eosin staining of formalin-
Figure 5. Effect of the HCV core
on the proliferation of NIH-3T3
cells. (A) NIH-3T3 cells were in-
fected with a retrovirus vector carry-
ing the core (pMX-core) or control
virus (pMX), then plated into 35
mm dishes and the cell number was
counted daily under normal growth
conditions. The mean cell number
with standard error of triplicate ex-
periments is shown. (B) Total cell
extracts from parental NIH-3T3
cells (parent) or infected cells were
immunoblotted with anti-phospho-
STAT3 or anti-STAT3. (C) The
NIH-3T3 cells infected with a
pMX-core retrovirus vector (NIH-
3T3/core) were further infected with
adenovirus carrying lacZ, SOCS3,
and Y705F-STAT3 (dnSTAT3) at
MOI 50. After infection, the cells
were plated and scored daily (tripli-
cate experiments). (D) Total cell ex-
tracts of infected cells were blotted
with anti-phospho-STAT3, anti-
STAT3 or anti-SOCS3. 
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fixed sections revealed that WT-STAT3/core-derived tu-
mor cells had multiple nucleoli, large nuclei, and frequent
mitoses (Fig. 7 B). The cells from Stat3-C–derived tumors
were more spindle-like and appeared to be more organized
than did cells from WT-STAT3/core- or 
 
v-src
 
–derived tu-
mors. WT-STAT3/core-derived tumor cells appeared to
be more similar to 
 
v-src
 
–derived tumors than did STAT3-
C–derived tumor cells (Fig. 7 B). Mice injected with pa-
rental NIH-3T3 cells or 3T3-core never developed tumors
(Table II). Western blot analysis of extracts derived from
STAT3/core-containing tumors revealed high levels of
STAT3 and core protein, hence the growing tumor cells
retained these two proteins (unpublished data). These re-
sults indicate that, by either core protein association or by
 
Table I.
 
Colony formation assay Plating efficiency of stable NIH-3T3–derived cell lines
Vector Colony number (SD) Cell line Inoculated cells Colony number (SD)
pMX 0 (0) NIH-3T3 10
 
6
 
0 (0)
pMX 
 
 
 
 WT-STAT3 0 (0) NIH-3T3-core 10
 
6
 
0 (0)
pMX 
 
  
 
STAT3-C 8 (4) WT-STAT3 10
 
6
 
0 (0)
pMX-core 0 (0) WT-STAT3/core 10
 
4
 
110 (32)
pMX-core 
 
  
 
WT-STAT3 10 (4) STAT3-C 10
 
4
 
92 (26)
pMX-core 
 
  
 
STAT3-C 20 (10) STAT3-C/core 10
 
4
 
222 (42)
 
v-src
 
96 (22)
 
v-src
 
10
 
3
 
180 (34)
NIH-3T3 cells were infected with pMX or pMX-core viruses and then transfected with WT-STAT3, STAT3-C, or 
 
v-src
 
. Transfected cells (106)
were plated in soft agar. 3 wk later, the colony number was determined. Results shown are the mean   SD of 3–8 experiments. The plating efficiency
of representative cell lines derived from soft agar or retrovirus infection (NIH-3T3-core) or clones selected in G418 (WT-STAT3) was determined
by plating the indicated number of cells into soft agar and counting the colonies after 10 d.
Figure 6. Transforming po-
tential of WT-STAT3 and core-
transfected cells. (A) NIH-3T3
cells or cells infected with the
pMX-core were transfected with
WT-STAT3 or STAT3-C and
plated into soft agar and photo-
graphed on day 10. In the lowest
panel, cells were infected with
adenovirus carrying dnSTAT3
(Ad-dnSTAT3) at MOI    50.
(B) The levels of endogenous
and exogenous STAT3 in
NIH-3T3 and comparison with
HepG2 cells. The same amount
of cell extracts (15  g protein/
lane) from parental 3T3, two independent transformants expressing the core and WT-STAT3
(core   WT-STAT3) and HepG2 cells were immunoblotted with anti-STAT3 antibody.
Linearity of the intensity of the band was observed between 5–40  g protein. (C) The effect
of adenovirus on the plating efficiency of cells lines expressing WT-STAT3/core derived
from soft agar. 106 cells were infected with the indicated adenovirus (MOI   50) and cultured
for 10 d. Colonies 0.1 mm or greater were scored.650 STAT3-dependent Transformation by HCV Core
point mutations, constitutively active STAT3 possesses
similar oncogenic potential.
Transcriptional Events Controlled by Core/Stat3 that may be
Related to Transformation and Cell Growth. To examine
events downstream from the constitutively active STAT3/
core or STAT3-C that promote tumorigenesis, we exam-
ined the expression of cyclin-D1 and Bcl-XL, which are
involved in cell-cycle progression and antiapoptosis, re-
spectively, and direct target genes of STAT3 (8). We also
examined SOCS3, which is induced by STAT3 (32, 33).
As shown in Fig. 8, there was a drastic increase in the con-
centration of cyclin D1 and Bcl-XL in cells transformed by
STAT3-C, WT-STAT3/core, and v-src. However, as non-
transformed NIH-3T3/core cells also expressed high levels
of cyclin D and Bcl-XL, these two STAT3 target genes
may play an important role in rapid proliferation (Fig. 5),
but are not sufficient for cellular transformation. It will be
important to identify new STAT3 target genes directly in-
volved in tumorigenesis.
We also observed the elevated expression of SOCS3 in
cells expressing the core protein (Fig. 8). This is consistent
with previous reports indicated that SOCS3 expression is
regulated by STAT3. Previously, HCV genome expression
was reported to inhibit interferon-STAT1 signaling by an
unknown mechanism (34). Up-regulation of SOCS3 may
be one mechanism involved in suppression of the IFN sig-
naling pathway (35), which confers the interferon-resis-
tance seen in HCV-infected cells.
Discussion
During the past several years, data have accumulated in-
dicating that human tumor samples contain constitutively
activated STAT3. Artificially created gain-of-function
mutant STAT3, STAT3-C, clearly demonstrated the tum-
origenic potential of STAT3. To date, no active mutation
has been found in STAT3 genes in human tumors. On the
other hand, there is abundant descriptive evidence that
links core protein to cellular transformation, but the
mechanism was not clarified. In our work, we noted a
strong link between HCV core protein and the constitu-
tive activation of STAT3, events which lead to growth
dysregulation. As our present study is overexpression sys-
tem of one of the viral proteins using cell lines and a
model mouse, we may not be able to simply apply our
conclusion to the physiological infection conditions.
Therefore, confirmation of our hypothesis by using hu-
man specimens infected with HCV is necessary in the fu-
ture study. However, our study demonstrated that STAT3
activation by the HCV core protein is an important step
for transformation in vitro. This will provide a new insight
into the mechanism of HCC development and a new
therapeutic target, i.e., STAT3.
As cells expressing the core alone were not tumorigenic,
for the appearance of HCC, some secondary ‘hit(s)’, such
as elevated expression of STAT3 or activation of ras (36),
must be necessary for the development of a malignant phe-
notype. Up-regulation of cyclin D1 and Bcl-XL may ex-
plain the increase in growth rate by activation of STAT3,
yet these two genes are not sufficient for cellular transfor-
mation. We are currently searching for genes specifically
expressed in transformed cells by WT-STAT3/core but
not in cells expressing the core or WT-STAT3 alone.
Yoshikawa and colleagues reported evidence that inacti-
vation of SOCS1 by gene methylation and the consequent
constitutive activation of cytokine-JAK/STAT (especially
STAT3) signaling pathways are responsible for growth of
HCCs (37). Their study as well as our data provide new in-
sights into the role of STAT3 in HCC development. We
also observed that colony formation of HepG2 cells in soft
agar can be inhibited by dnSTAT3 adenovirus (unpub-
lished data). These data strongly suggest that constitutive
activation of STAT3 may play an important role in colony
formation of HCC cells in soft agar. As core protein ex-
pression occurred only in the presence of HCV (HCV ge-
nome is not integrated into hepatocyte DNA), core/
STAT3 interaction may be an initial step of STAT3 activa-
tion, then loss of SOCS-1 expression takes over the consti-
tutive activation of STAT3. Thus, the constitutive activa-
tion of STAT3 induced by viral or cellular oncogenes, or
loss of suppressors presents an attractive target for drug dis-
covery with the potential of inducing cell death or inhibit-
ing the growth of human HCV-mediated hepatocarcino-
mas. Our dominant negative STAT3 adenovirus or a
minimal peptide that inhibits STAT3 signaling developed
by Turkson et al. (38) could be useful as a lead for gene
therapy or peptidomimetic drug design. Moreover, the
Table II. Tumors in Nude Mice
Cell line Tumor size (cm) cm3
NIH-3T3 ND
NIH-3T3-core ND
WT-STAT3 ND
WT-STAT3/core
Clone 1 0.8   0.8   1.0 0.64
0.4   0.5   0.8 0.16
0.8   0.6   0.8 0.38
Clone 2 1.8   1.5   1.5 4.05
1.6   1.2   1.2 2.34
1.2   1.0   1.0 1.20
STAT3-C 1.2   0.8   1.0 0.96
1.2   1.5   1.6 2.88
1.8   1.2   1.0 2.16
v-src 3.0   4.0   2.5 30.0
Cells (106) from NIH-3T3, v-src, STAT3-C, and WT-STAT3/core cell
lines were injected into the flank of athymic nude mice. Each cell line
was determined in 2–3 different mice. Tumor size was determined 3 wk
after injection. ND, not detected.651 Yoshida et al.
present experiments provide the tools to pursue the basis of
STAT3-mediated transformation, including a search of
novel STAT3 target genes and heighten interest in the mo-
lecular mechanism of the constitutive activation of STAT3
seen in cancer. Also, other viral oncoproteins or cellular
protooncogenes may cooperate with STAT3, thereby con-
tributing to malignant transformation.
As the core protein has no tyrosine kinase activity, the
manner in which it induces tyrosine phosphorylation of
STAT-3 is not clear. Our experiments suggest that coex-
pression of the core resulted a decrease in the dephosphory-
lation rate of phosphorylated STAT3 (Fig. 4 C). Thus, the
core may prevent access of phosphatases to the STAT3, or
the core recruits a tyrosine kinase to STAT3. However, we
detected no tyrosine kinase activity in the immunoprecipi-
tates with anti-core antibody. Therefore, we suspect that
the former case is more likely. This may provide a novel ap-
proach to selectively regulate the activation of STAT3
without affecting other cytokine signaling pathways.
Figure 7. Tumorigenicity of cells transformed of WT-STAT3 and core-transfected cells. (A) WT-STAT3/core or STAT3-C transformed cell lines
were injected into nude mice, and the mice were photographed 3 wk later. (B) Paraffin sections from WT-STAT3/core, Stat3-C and v-src-containing
tumors were stained with hematoxylin and eosin and viewed at 400  magnification.
Figure 8. Cell extracts were prepared from parental NIH-3T3 cells
(parent; lane 1), core-infected cells (core) (lane 2), and representative
clones isolated from soft agar (STAT3   core [lane 4], STAT3-C [lane
5], and v-src [lane 6]), and NIH-3T3 transformant expressing WT-STAT3
(lane 3), then immunoblotted with the indicated antibodies.652 STAT3-dependent Transformation by HCV Core
Although our pX-core Tg mice developed tumors in the
skin and muscle, HCC was not evident in these Tg mice.
Furthermore, HCV structural protein Tg mice developed
spontaneous focal infiltration of lymphocytes, hepatocyte
necrosis, degeneration, and altered foci with mitotic hepa-
tocytes, but had no neoplastic or cancerous lesions in liver
by the age of 20 mo (39). However, Lerat et al. reported
that hepatocellular adenoma or carcinoma developed in
older male Tg mice expressing RNA of the complete viral
polyprotein in the liver (40). Therefore, a heterologous
overexpression system of structural and nonstructural pro-
teins may have stronger oncogenic potential than does the
expression of individual viral proteins. In this context, it is
interesting that whole HCV genome expression more
strongly induced STAT3 phosphorylation as compared
with the core protein alone (Fig. 2 E). Transcriptional ac-
tivity of STAT3 was also more strongly upregulated by the
full HCV genome than by the core alone (unpublished
data). Therefore, STAT3 activation can also occur not only
by core protein expression but also by expression of whole
HCV proteins. Recently, a similar constitutive activation
of STAT3 by the nonstructural HCV protein, NS5A has
been noted (41). In this case, oxidative stress and intracellu-
lar Ca2  was involved, since antioxidants or Ca2  chelators
eliminated the NS5A-induced activation of STAT3. In
contrast, we observe no effects of these agents on core-
mediated STAT3 activation (unpublished data), suggesting
that STAT3 may be activated by multiple mechanisms and
by different viral proteins. Further study is underway to de-
fine the relationship between STAT3 activation, transfor-
mation and full HCV protein expression.
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